{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:06:50Z","timestamp":1793225210795,"version":"4.5.0"},"reference-count":108,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000064","name":"Banting and Best Diabetes Centre, University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000191","name":"Kidney Foundation of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015452","name":"Canadian Society of Nephrology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009227","name":"Department of Medicine, University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009227","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Volume overload represents a hallmark clinical feature linked to the development and progression of heart failure (HF). Alleviating signs and symptoms of volume overload represents a foundational HF treatment target that is achieved using loop diuretics in the acute and chronic setting. Recent work has provided evidence to support guideline-directed medical therapies, such as sodium glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid receptor (MR) antagonists, as important adjunct diuretics that may act synergistically when used with background loop diuretics in people with chronic HF. Furthermore, there is growing interest in understanding the role of SGLT2 inhibitors, carbonic anhydrase inhibitors, thiazide diuretics, and MR antagonists in treating volume overload in patients hospitalized for acute HF, particularly in the setting of loop diuretic resistance. Thus, the current review demonstrates that: (i) SGLT2 inhibitors and MR antagonists confer long-term cardioprotection in chronic HF patients but it is unclear whether natriuresis or diuresis represents the primary mechanisms for this benefit, (ii) SGLT2 inhibitors, carbonic anhydrase inhibitors, and thiazide diuretics increase natriuresis in the acute HF setting, but implications on long-term outcomes remain unclear and warrants further investigation, and (iii) a multi-nephron segment approach, using agents that act on distinct segments of the nephron, potentiate diuresis to alleviate signs and symptoms of volume overload in acute HF.<\/jats:p>","DOI":"10.1093\/ndt\/gfae058","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T06:37:35Z","timestamp":1709275055000},"page":"1392-1403","source":"Crossref","is-referenced-by-count":14,"title":["Proximal versus distal diuretics in congestive heart failure"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1990-6481","authenticated-orcid":false,"given":"Massimo","family":"Nardone","sequence":"first","affiliation":[{"name":"University Health Network, Division of Nephrology, Department of Medicine, University of Toronto , Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas S","family":"Sridhar","sequence":"additional","affiliation":[{"name":"University Health Network, Division of Nephrology, Department of Medicine, University of Toronto , Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Yau","sequence":"additional","affiliation":[{"name":"University Health Network, Division of Nephrology, Department of Medicine, University of Toronto , Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayodele","family":"Odutayo","sequence":"additional","affiliation":[{"name":"University Health Network, Division of Nephrology, Department of Medicine, University of Toronto , Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z I","family":"Cherney","sequence":"additional","affiliation":[{"name":"University Health Network, Division of Nephrology, Department of Medicine, University of Toronto , Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"2024083002360110500_bib1","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/eurheartj\/ehx035","article-title":"Renal sodium avidity in heart failure: from pathophysiology to treatment strategies","volume":"38","author":"Mullens","year":"2017","journal-title":"Eur Heart J"},{"key":"2024083002360110500_bib2","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jacc.2019.12.059","article-title":"Diuretic therapy for patients with heart failure: JACC state-of-the-art review","volume":"75","author":"Felker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2024083002360110500_bib3","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1161\/CIRCULATIONAHA.119.039920","article-title":"Prognostic implications of congestion on physical examination among contemporary patients with heart failure and reduced ejection fraction","volume":"140","author":"Selvaraj","year":"2019","journal-title":"Circulation"},{"key":"2024083002360110500_bib4","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.jacc.2021.07.046","article-title":"Prognostic importance of NT-proBNP and effect of Empagliflozin in the EMPEROR-reduced trial","volume":"78","author":"Januzzi","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2024083002360110500_bib5","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2024083002360110500_bib6","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: executive summary","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2024083002360110500_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion\u2014A position statement from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Mullens","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2024083002360110500_bib8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.cardfail.2018.02.002","article-title":"Determinants of diuretic responsiveness and associated outcomes during acute heart failure hospitalization: an analysis from the NHLBI heart failure network clinical trials","volume":"24","author":"Kiernan","year":"2018","journal-title":"J Card Fail"},{"key":"2024083002360110500_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1067\/mhj.2002.123144","article-title":"Diuretic resistance predicts mortality in patients with advanced heart failure","volume":"144","author":"Neuberg","year":"2002","journal-title":"Am Heart J"},{"key":"2024083002360110500_bib10","first-page":"e008351","article-title":"Diuretic changes, health care resource utilization, and clinical outcomes for heart failure with reduced ejection fraction: from the change the management of patients with heart failure registry","volume":"14","author":"Khan","year":"2021","journal-title":"Circulation: Heart Failure"},{"key":"2024083002360110500_bib11","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/eurheartj\/ehad283","article-title":"Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial","volume":"44","author":"Chatur","year":"2023","journal-title":"Eur Heart J"},{"key":"2024083002360110500_bib12","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1001\/jamacardio.2023.1090","article-title":"Safety and efficacy of Empagliflozin and diuretic use in patients with heart failure and preserved ejection fraction: a post hoc analysis of the EMPEROR-preserved trial","volume":"8","author":"Butler","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2024083002360110500_bib13","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/ehad266","article-title":"Great debate: in patients with decompensated heart failure, acetazolamide in addition to loop diuretics is the first choice","volume":"44","author":"Mullens","year":"2023","journal-title":"Eur Heart J"},{"key":"2024083002360110500_bib14","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with Empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2024083002360110500_bib15","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2024083002360110500_bib16","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2024083002360110500_bib17","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2024083002360110500_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2024083002360110500_bib19","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med"},{"key":"2024083002360110500_bib20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00232-001-0036-y","article-title":"Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat","volume":"182","author":"Vestri","year":"2001","journal-title":"J Membr Biol"},{"key":"2024083002360110500_bib21","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose cotransporter-2 inhibition in heart failure","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation"},{"key":"2024083002360110500_bib22","doi-asserted-by":"crossref","first-page":"F712","DOI":"10.1152\/ajprenal.00264.2020","article-title":"A role for tubular Na+\/H+ exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin","volume":"319","author":"Onishi","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"2024083002360110500_bib23","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"2024083002360110500_bib24","doi-asserted-by":"crossref","first-page":"154918","DOI":"10.1016\/j.metabol.2021.154918","article-title":"Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease","volume":"126","author":"Liu","year":"2022","journal-title":"Metabolism"},{"key":"2024083002360110500_bib25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.kint.2020.02.041","article-title":"The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?","volume":"98","author":"Hesp","year":"2020","journal-title":"Kidney Int"},{"key":"2024083002360110500_bib26","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"2024083002360110500_bib27","first-page":"189","article-title":"Empagliflozin in heart failure: regional nephron sodium handling effects","volume-title":"J Am Soc Nephrol","author":"Rao","year":"2023"},{"key":"2024083002360110500_bib28","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1093\/eurheartj\/ehac495","article-title":"Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme","volume":"43","author":"Zannad","year":"2022","journal-title":"Eur Heart J"},{"key":"2024083002360110500_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-019-0852-y","article-title":"Effect of SGLT2 inhibitors on body composition, fluid status and renin\u2013angiotensin\u2013aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy","volume":"18","author":"Schork","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"2024083002360110500_bib30","doi-asserted-by":"crossref","first-page":"e14360","DOI":"10.14814\/phy2.14360","article-title":"Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume","volume":"8","author":"Masuda","year":"2020","journal-title":"Physiol Rep"},{"key":"2024083002360110500_bib31","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1161\/CIRCULATIONAHA.120.048739","article-title":"Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure","volume":"142","author":"Mordi","year":"2020","journal-title":"Circulation"},{"key":"2024083002360110500_bib32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00392-022-02119-7","article-title":"The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial","volume":"112","author":"Kolwelter","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"2024083002360110500_bib33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2213-8587(20)30382-X","article-title":"Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial","volume":"9","author":"Jensen","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024083002360110500_bib34","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/ehf2.13683","article-title":"Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction","volume":"9","author":"Nakashima","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2024083002360110500_bib35","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00392-022-02049-4","article-title":"Body fluid regulation via chronic inhibition of sodium\u2013glucose cotransporter-2 in patients with heart failure: a post hoc analysis of the CANDLE trial","volume":"112","author":"Fujiki","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"2024083002360110500_bib36","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","article-title":"Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"key":"2024083002360110500_bib37","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1681\/ASN.0000000000000271","article-title":"Effects of Empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease","volume":"35","author":"Mayne","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2024083002360110500_bib38","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1016\/j.jacc.2020.10.005","article-title":"Effect of Empagliflozin on hemodynamics in patients with heart failure and reduced ejection fraction","volume":"76","author":"Omar","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2024083002360110500_bib39","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","article-title":"Empagliflozin effects on pulmonary artery pressure in patients with heart failure","volume":"143","author":"Nassif","year":"2021","journal-title":"Circulation"},{"key":"2024083002360110500_bib40","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1002\/ehf2.13615","article-title":"Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial","volume":"8","author":"Fitchett","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2024083002360110500_bib41","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of Empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"key":"2024083002360110500_bib42","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1001\/jamacardio.2022.3750","article-title":"Time to clinical benefit of Dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified secondary analysis of the DELIVER randomized clinical trial","volume":"7","author":"Vaduganathan","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2024083002360110500_bib43","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1111\/dom.15112","article-title":"Kidney protection with canagliflozin: a combined analysis of the randomized CANVAS program and CREDENCE trials","volume":"25","author":"Sridhar","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2024083002360110500_bib44","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.jacc.2021.01.033","article-title":"Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload: eMPEROR-reduced trial","volume":"77","author":"Packer","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2024083002360110500_bib45","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/CIRCULATIONAHA.120.047077","article-title":"Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF","volume":"142","author":"Jackson","year":"2020","journal-title":"Circulation"},{"key":"2024083002360110500_bib46","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2024083002360110500_bib47","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ejhf.2066","article-title":"Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure","volume":"23","author":"Boorsma","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2024083002360110500_bib48","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.122.059038","article-title":"Effects of early Empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF)","volume":"146","author":"Schulze","year":"2022","journal-title":"Circulation"},{"key":"2024083002360110500_bib49","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1093\/eurheartj\/ehad341","article-title":"Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics","volume":"44","author":"Yeoh","year":"2023","journal-title":"Eur Heart J"},{"key":"2024083002360110500_bib50","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"2024083002360110500_bib51","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJM195305212482102","article-title":"The use of Diamox, a carbonic anhydrase inhibitor, as an oral diuretic in patients with congestive heart failure","volume":"248","author":"Friedberg","year":"1953","journal-title":"N Engl J Med"},{"key":"2024083002360110500_bib52","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0140-6736(56)90105-2","article-title":"Acetazolamide (Diamox) in the treatment of congestive heart failure","volume":"267","author":"Hanley","year":"1956","journal-title":"Lancet North Am Ed"},{"key":"2024083002360110500_bib53","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/ejhf.1478","article-title":"Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance","volume":"21","author":"Verbrugge","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2024083002360110500_bib54","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","article-title":"Acetazolamide in acute decompensated heart failure with volume overload","volume":"387","author":"Mullens","year":"2022","journal-title":"N Engl J Med"},{"key":"2024083002360110500_bib55","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.jacc.2023.03.400","article-title":"Natriuretic response to acetazolamide in patients with acute heart failure and volume overload","volume":"81","author":"Verbrugge","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2024083002360110500_bib56","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/eurheartj\/ehad236","article-title":"Pre-treatment bicarbonate levels and decongestion by acetazolamide: the ADVOR trial","volume":"44","author":"Martens","year":"2023","journal-title":"Eur Heart J"},{"key":"2024083002360110500_bib57","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1161\/HYPERTENSIONAHA.120.15205","article-title":"Pathophysiology of diuretic resistance and its implications for the management of chronic heart failure","volume":"76","author":"Wilcox","year":"2020","journal-title":"Hypertension"},{"key":"2024083002360110500_bib58","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/CIRCULATIONAHA.122.062486","article-title":"Decongestion with acetazolamide in acute decompensated heart failure across the spectrum of left ventricular ejection fraction: a prespecified analysis from the ADVOR trial","volume":"147","author":"Martens","year":"2023","journal-title":"Circulation"},{"key":"2024083002360110500_bib59","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1681\/ASN.2016111178","article-title":"Compensatory distal reabsorption drives diuretic resistance in Human heart failure","volume":"28","author":"Rao","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2024083002360110500_bib60","first-page":"157","article-title":"Diuretic strategies for loop Diuretic resistance in acute heart failure: the 3T trial","volume":"8","author":"Cox","year":"2020","journal-title":"JACC: Heart Fail"},{"key":"2024083002360110500_bib61","doi-asserted-by":"crossref","first-page":"e009149","DOI":"10.1161\/JAHA.118.009149","article-title":"Outcomes associated with a strategy of adjuvant metolazone or high-dose loop diuretics in acute decompensated heart failure: a propensity analysis","volume":"7","author":"Brisco-Bacik","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2024083002360110500_bib62","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/ehjacc\/zuac006","article-title":"Comparison of chlorthalidone and spironolactone as additional diuretic therapy in patients with acute heart failure and preserved ejection fraction","volume":"11","author":"Ll\u00e0cer","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2024083002360110500_bib63","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.cardfail.2022.05.011","article-title":"Metolazone versus intravenous chlorothiazide for decompensated heart failure sequential nephron blockade: a retrospective cohort study","volume":"28","author":"Cisowska","year":"2022","journal-title":"J Card Fail"},{"key":"2024083002360110500_bib64","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0002-8703(75)90041-1","article-title":"The supra-additive natriuretic effect addition of bendroflumethiazide and bumetanide in congestive heart failure: permutation trial tests in patients in long-term treatment with bumetanide","volume":"89","author":"Sigurd","year":"1975","journal-title":"Am Heart J"},{"key":"2024083002360110500_bib65","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.3390\/jcm10184207","article-title":"Effects of metolazone administration on congestion, diuretic response and renal function in patients with advanced heart failure","volume":"10","author":"Palazzuoli","year":"2021","journal-title":"J Clin Med"},{"key":"2024083002360110500_bib66","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1093\/oxfordjournals.eurheartj.a014805","article-title":"Combination of high-dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure","volume":"17","author":"Dormans","year":"1996","journal-title":"Eur Heart J"},{"key":"2024083002360110500_bib67","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0140-6736(90)90148-X","article-title":"Metolazone in treatment of severe refractory congestive cardiac failure","volume":"335","author":"Kiyingi","year":"1990","journal-title":"Lancet North Am Ed"},{"key":"2024083002360110500_bib68","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/hrt.71.2.146","article-title":"Combination diuretic treatment in severe heart failure: a randomised controlled trial","volume":"71","author":"Channer","year":"1994","journal-title":"Heart"},{"key":"2024083002360110500_bib69","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/eurheartj\/ehac689","article-title":"Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial","volume":"44","author":"Trulls","year":"2023","journal-title":"Eur Heart J"},{"key":"2024083002360110500_bib70","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1172\/JCI103385","article-title":"The effect of changes in body sodium on extracellular fluid volume and aldostrone and soidu excretion by normal and edematous men","volume":"35","author":"Duncan","year":"1956","journal-title":"J Clin Invest"},{"key":"2024083002360110500_bib71","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"2024083002360110500_bib72","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12933-023-01899-0","article-title":"The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction","volume":"22","author":"Kintscher","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2024083002360110500_bib73","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"2024083002360110500_bib74","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2024083002360110500_bib75","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfae004","article-title":"When to use either spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases","author":"Kobayashi","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2024083002360110500_bib76","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2024083002360110500_bib77","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2024083002360110500_bib78","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2024083002360110500_bib79","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"2024083002360110500_bib80","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"2024083002360110500_bib81","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/bmj.2.5195.339","article-title":"Use of spironolactone and hydrochlorothiazide in treatment of oedema","volume":"2","author":"Farrelly","year":"1960","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2024083002360110500_bib82","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1159\/000168356","article-title":"Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention","volume":"11","author":"Hensen","year":"1991","journal-title":"Am J Nephrol"},{"key":"2024083002360110500_bib83","doi-asserted-by":"crossref","first-page":"A21","DOI":"10.1016\/0002-9149(93)90241-4","article-title":"Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor","volume":"71","author":"van Vliet Andr\u00e9","year":"1993","journal-title":"Am J Cardiol"},{"key":"2024083002360110500_bib84","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/S0735-1097(02)02382-3","article-title":"Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy","volume":"40","author":"Rousseau","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2024083002360110500_bib85","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/eurheartj\/ehaa758","article-title":"The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart \u2018OMics\u2019 in AGEing (HOMAGE) randomized clinical trial","volume":"42","author":"Cleland","year":"2021","journal-title":"Eur Heart J"},{"key":"2024083002360110500_bib86","doi-asserted-by":"crossref","first-page":"e009295","DOI":"10.1161\/CIRCHEARTFAILURE.121.009295","article-title":"Timing of statistical benefit of mineralocorticoid receptor antagonists among patients with heart failure and post-myocardial infarction","volume":"15","author":"Bedrouni","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2024083002360110500_bib87","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/ejhf.1917","article-title":"Diuretic and renal effects of spironolactone and heart failure hospitalizations: a TOPCAT Americas analysis","volume":"22","author":"Kalogeropoulos","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2024083002360110500_bib88","first-page":"241","article-title":"Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial","volume":"5","author":"Anand","year":"2017","journal-title":"JACC: Heart Fail"},{"key":"2024083002360110500_bib89","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1001\/jamacardio.2017.2198","article-title":"Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial","volume":"2","author":"Butler","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2024083002360110500_bib90","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jamacardio.2017.4370","article-title":"Interpretation of the ATHENA trial\u2014caveats and future directions","volume":"3","author":"Ferreira","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2024083002360110500_bib91","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2005.02.095","article-title":"Vasopressin antagonism in heart failure","volume":"46","author":"Goldsmith","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2024083002360110500_bib92","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1161\/CIRCHEARTFAILURE.110.960096","article-title":"Increased 90-day mortality in patients with acute heart failure with elevated copeptin","volume":"4","author":"Maisel","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2024083002360110500_bib93","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","article-title":"Vasopressin V2-receptor blockade with Tolvaptan in patients with chronic heart failure","volume":"107","author":"Gheorghiade","year":"2003","journal-title":"Circulation"},{"key":"2024083002360110500_bib94","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","article-title":"Effects of Tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure. A randomized controlled trial","volume":"291","author":"Gheorghiade","year":"2004","journal-title":"JAMA"},{"key":"2024083002360110500_bib95","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral Tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"2024083002360110500_bib96","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2016.09.004","article-title":"Efficacy and safety of Tolvaptan in patients hospitalized with acute heart failure","volume":"69","author":"Felker","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2024083002360110500_bib97","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jacc.2016.12.035","article-title":"Short-term effects of Tolvaptan in patients with acute heart failure and volume overload","volume":"69","author":"Konstam","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2024083002360110500_bib98","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a selective oral Vasopressin V2-receptor antagonist, for hyponatremia","volume":"355","author":"Schrier","year":"2006","journal-title":"N Engl J Med"},{"key":"2024083002360110500_bib99","first-page":"73","article-title":"A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction","volume":"10","author":"Tromp","year":"2022","journal-title":"JACC: Heart Fail"},{"key":"2024083002360110500_bib100","article-title":"Pharmacological treatments in heart failure with mildly reduced and preserved ejection fraction: systematic review and network meta-analysis","volume-title":"JACC: Heart Fail","author":"Zafeiropoulos","year":"2023"},{"key":"2024083002360110500_bib101","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/ejhf.2149","article-title":"Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction","volume":"23","author":"Packer","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2024083002360110500_bib102","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamacardio.2021.0496","article-title":"Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure\u2014optimizing therapy with the need for speed","volume":"6","author":"Greene","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2024083002360110500_bib103","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"2024083002360110500_bib104","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","article-title":"Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: eMPEROR-reduced","volume":"77","author":"Ferreira","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2024083002360110500_bib105","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"2024083002360110500_bib106","doi-asserted-by":"crossref","first-page":"ehaa946.0939","DOI":"10.1093\/ehjci\/ehaa946.0939","article-title":"Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF","volume":"41","author":"Kristensen","year":"2020","journal-title":"Eur Heart J"},{"key":"2024083002360110500_bib107","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cardfail.2021.07.016","article-title":"Multinephron segment diuretic therapy to overcome diuretic resistance in acute heart failure: a single-center experience","volume":"28","author":"Cox","year":"2022","journal-title":"J Card Fail"},{"key":"2024083002360110500_bib108","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.2215\/CJN.0000000000000188","article-title":"Combination diuretic therapy to counter renal sodium avidity in acute heart failure: trials and tribulations","volume":"18","author":"Kazory","year":"2023","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfae058\/57768596\/gfae058.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/9\/1392\/58962878\/gfae058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/9\/1392\/58962878\/gfae058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T02:37:12Z","timestamp":1724985432000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/39\/9\/1392\/7616922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":108,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,2,29]]},"published-print":{"date-parts":[[2024,8,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfae058","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,2,29]]}}}